Alto Neuroscience股份在2026年3月16日上升8.8%至24.22美元, Alto Neuroscience shares rose 8.8% to $24.22 on March 16, 2026, after reporting 2025 results and securing $120 million in funding for its depression drug.

2026年3月16日, Alto Neuroscience 股份上升8.81%至24.22美元, Alto Neuroscience shares rose 8.81% to $24.22 on March 16, 2026, following the release of fiscal year 2025 results and a $120 million private placement financing. 该公司报告说,2025年净损失为6 320万美元,即每股2.19美元,略高于2024年的损失,尽管业务开支下降。 The company reported a net loss of $63.2 million, or $2.19 per share, for 2025, slightly wider than 2024’s loss, though operating expenses declined. 这笔资金将支持ALTO-207的开发,包括计划进行的抗治疗性抑郁症第三阶段试验,预计形式现金将达到2.75亿美元。 The funding will support the development of ALTO-207, including a planned Phase 3 trial for treatment-resistant depression, with pro forma cash expected to reach $275 million. 该库存达到52周的最高水平,为24.70美元,并接近其上层范围关闭。 The stock hit a 52-week high of $24.70 and closed near its upper range.